Patients	O
with	O
Crohns	B-DISEASE
disease	I-DISEASE
exhibited	O
reduced	O
Faecalibacterium	B-BACTERIA
prausnitzii	I-BACTERIA
levels	O
during	O
intestinal	B-PROCESS
inflammation	I-PROCESS
processes.	I-PROCESS

The	O
antibiotic	B-PROCESS
treatment	I-PROCESS
significantly	O
altered	O
butyrate	B-PROCESS
production	I-PROCESS
and	O
disrupted	O
epithelial	B-PROCESS
cell	I-PROCESS
proliferation	I-PROCESS
mechanisms.	I-PROCESS

Helicobacter	B-BACTERIA
pylori	I-BACTERIA
colonization	I-BACTERIA
in	O
gastric	O
mucosa	O
triggers	O
chronic	O
inflammatory	B-PROCESS
responses	I-PROCESS
in	O
peptic	B-DISEASE
ulcer	I-DISEASE
patients.	O

Researchers	O
identified	O
elevated	O
trimethylamine	B-CHEMICAL
N-oxide	I-CHEMICAL
concentrations	O
correlating	O
with	O
cardiovascular	B-DISEASE
disease	I-DISEASE
risk	O
factors.	O

Multiple	B-DISEASE
sclerosis	I-DISEASE
patients	O
showed	O
distinct	O
cerebrospinal	B-CHEMICAL
fluid	I-CHEMICAL
metabolite	I-CHEMICAL
profiles	O
including	O
altered	O
tryptophan	B-PROCESS
catabolism.	I-PROCESS

Clostridioides	B-DISEASE
difficile	I-DISEASE
infection	I-DISEASE
severity	O
increased	O
with	O
depleted	O
Bacteroides	B-BACTERIA
fragilis	I-BACTERIA
populations	O
in	O
hospitalized	O
patients.	O

The	O
probiotic	B-PROCESS
intervention	I-PROCESS
restored	O
lactate	B-PROCESS
metabolism	I-PROCESS
while	O
reducing	O
lipopolysaccharide-induced	B-PROCESS
inflammatory	I-PROCESS
cytokine	I-PROCESS
production.	I-PROCESS

Parkinsons	B-DISEASE
disease	I-DISEASE
progression	O
correlated	O
with	O
decreased	O
Prevotella	B-BACTERIA
abundance	O
and	O
impaired	O
dopamine	B-PROCESS
synthesis	I-PROCESS
pathways.	I-PROCESS

Metformin	B-CHEMICAL
treatment	O
modulated	O
Akkermansia	B-BACTERIA
muciniphila	I-BACTERIA
growth	O
and	O
improved	O
glucose	B-PROCESS
homeostasis	I-PROCESS
in	O
diabetic	O
patients.	O

Patients	O
diagnosed	O
with	O
irritable	B-DISEASE
bowel	I-DISEASE
syndrome	I-DISEASE
demonstrated	O
elevated	O
hydrogen	B-CHEMICAL
sulfide	I-CHEMICAL
levels	O
and	O
altered	O
Desulfovibrio	B-BACTERIA
colonization.	O

The	O
ketogenic	O
diet	O
intervention	O
increased	O
beta-hydroxybutyrate	B-CHEMICAL
concentrations	O
and	O
modified	O
Ruminococcus	B-BACTERIA
bacterial	O
populations.	O

Alzheimers	B-DISEASE
disease	I-DISEASE
patients	O
exhibited	O
reduced	O
short-chain	B-PROCESS
fatty	I-PROCESS
acid	I-PROCESS
production	I-PROCESS
alongside	O
increased	O
neuroinflammatory	B-PROCESS
marker	I-PROCESS
expression.	O

Colorectal	B-DISEASE
cancer	I-DISEASE
development	O
associated	O
with	O
enhanced	O
Fusobacterium	B-BACTERIA
nucleatum	I-BACTERIA
adhesion	O
and	O
disrupted	O
DNA	B-PROCESS
repair	I-PROCESS
mechanisms.	I-PROCESS

The	O
Mediterranean	O
diet	O
increased	O
Bifidobacterium	B-BACTERIA
longum	I-BACTERIA
abundance	O
while	O
reducing	O
C-reactive	B-CHEMICAL
protein	I-CHEMICAL
inflammatory    O
biomarkers.	O

Rheumatoid	B-DISEASE
arthritis	I-DISEASE
patients	O
showed	O
elevated	O
citrullinated	B-CHEMICAL
protein	I-CHEMICAL
levels	O
and	O
decreased	O
Lactobacillus	B-BACTERIA
casei	I-BACTERIA
gut	O
colonization.	O

Antibiotic-associated	B-DISEASE
diarrhea	O
resulted	O
from	O
Clostridium	B-BACTERIA
perfringens	I-BACTERIA
overgrowth	O
and	O
impaired	O
mucin	B-PROCESS
glycoprotein	I-PROCESS
synthesis.	O

The	O
fecal	B-PROCESS
microbiota	I-PROCESS
transplantation	I-PROCESS
restored	O
microbial	O
diversity	O
and	O
normalized	O
bile	B-PROCESS
acid	I-PROCESS
metabolism	I-PROCESS
in	O
recipients.	O

Type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
progression	O
involved	O
altered	O
indole-3-propionic	B-CHEMICAL
acid	I-CHEMICAL
levels	O
and	O
reduced	O
Roseburia	B-BACTERIA
intestinalis	I-BACTERIA
populations.	O

Hepatic	B-DISEASE
encephalopathy	I-DISEASE
patients	O
demonstrated	O
increased	O
ammonia	B-CHEMICAL
concentrations	O
and	O
dysregulated	O
Enterobacteriaceae	B-BACTERIA
growth	O
patterns.	O

The	O
prebiotic	B-PROCESS
supplementation	I-PROCESS
enhanced	O
Akkermansia	B-BACTERIA
growth	O
while	O
stimulating	O
regulatory	B-PROCESS
T-cell	I-PROCESS
differentiation	I-PROCESS
processes.	I-PROCESS

Ulcerative	B-DISEASE
colitis	I-DISEASE
exacerbation	O
correlated	O
with	O
decreased	O
Faecalibacterium	B-BACTERIA
abundance	O
and	O
elevated	O
calprotectin	B-CHEMICAL
inflammatory	O
markers.	O

Obesity-related	B-DISEASE
metabolic	I-DISEASE
dysfunction	I-DISEASE
involved	O
altered	O
leptin	B-CHEMICAL
signaling	O
and	O
increased	O
Firmicutes	B-BACTERIA
to	O
Bacteroidetes	B-BACTERIA
ratios.	O

The	O
synbiotic	B-PROCESS
treatment	I-PROCESS
improved	O
intestinal	B-PROCESS
barrier	I-PROCESS
function	I-PROCESS
through	O
enhanced	O
tight	B-PROCESS
junction	I-PROCESS
protein	I-PROCESS
expression.	O

Autism	B-DISEASE
spectrum	I-DISEASE
disorder	I-DISEASE
children	O
exhibited	O
distinct	O
urinary	B-CHEMICAL
metabolite	I-CHEMICAL
patterns	O
including	O
altered	O
GABA	B-PROCESS
neurotransmitter	I-PROCESS
metabolism.	I-PROCESS

Celiac	B-DISEASE
disease	I-DISEASE
patients	O
showed	O
increased	O
zonulin	B-CHEMICAL
permeability	O
markers	O
and	O
reduced	O
Bifidobacterium	B-BACTERIA
breve	I-BACTERIA
colonization	O
levels.	O

Periodontitis	B-DISEASE
severity	O
correlated	O
with	O
elevated	O
Porphyromonas	B-BACTERIA
gingivalis	I-BACTERIA
levels	O
and	O
increased	O
interleukin-6	B-PROCESS
inflammatory	I-PROCESS
cytokine	I-PROCESS
production.	I-PROCESS

The	O
mouthwash	B-PROCESS
intervention	I-PROCESS
reduced	O
Streptococcus	B-BACTERIA
mutans	I-BACTERIA
colonization	O
while	O
preserving	O
beneficial	O
Streptococcus	B-BACTERIA
sanguinis	I-BACTERIA
populations.	O

Oral	B-DISEASE
squamous	I-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
patients	O
demonstrated	O
altered	O
Candida	B-BACTERIA
albicans	I-BACTERIA
overgrowth	O
and	O
disrupted	O
epithelial	B-PROCESS
barrier	I-PROCESS
function.	I-PROCESS

Dental	B-DISEASE
caries	I-DISEASE
progression	O
involved	O
enhanced	O
Lactobacillus	B-BACTERIA
acidophilus	I-BACTERIA
acid	B-PROCESS
production	I-PROCESS
and	O
enamel	B-PROCESS
demineralization	I-PROCESS
processes.	I-PROCESS

The	O
probiotic	B-PROCESS
lozenges	I-PROCESS
increased	O
Lactobacillus	B-BACTERIA
reuteri	I-BACTERIA
abundance	O
while	O
reducing	O
halitosis-associated	O
volatile	B-CHEMICAL
sulfur	I-CHEMICAL
compounds.	I-CHEMICAL

Sj√∂grens	B-DISEASE
syndrome	I-DISEASE
patients	O
exhibited	O
decreased	O
saliva	O
production	O
and	O
altered	O
Prevotella	B-BACTERIA
melaninogenica	I-BACTERIA
oral	O
colonization	O
patterns.	O

Gingivitis	B-DISEASE
development	O
associated	O
with	O
increased	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
levels	O
and	O
enhanced	O
Tannerella	B-BACTERIA
forsythia	I-BACTERIA
biofilm	B-PROCESS
formation.	I-PROCESS

The	O
chlorhexidine	B-CHEMICAL
treatment	O
effectively	O
reduced	O
Aggregatibacter	B-BACTERIA
actinomycetemcomitans	I-BACTERIA
while	O
maintaining	O
oral	O
microbiome	B-PROCESS
diversity.	I-PROCESS

Head	O
and	O
neck	O
cancer	B-DISEASE
patients	O
showed	O
elevated	O
Fusobacterium	B-BACTERIA
periodonticum	I-BACTERIA
levels	O
and	O
impaired	O
immune	B-PROCESS
surveillance	I-PROCESS
mechanisms.	I-PROCESS

Orthodontic	B-PROCESS
treatment	I-PROCESS
altered	O
oral	O
pH	O
levels	O
and	O
modified	O
Actinomyces	B-BACTERIA
naeslundii	I-BACTERIA
adhesion	O
to	O
dental	O
surfaces.	O

The	O
xylitol	B-CHEMICAL
supplementation	O
inhibited	O
Streptococcus	B-BACTERIA
sobrinus	I-BACTERIA
growth	O
while	O
promoting	O
remineralization	B-PROCESS
processes	I-PROCESS
in	O
tooth	O
enamel.	O

Oral	B-DISEASE
lichen	I-DISEASE
planus	I-DISEASE
patients	O
demonstrated	O
increased	O
matrix	B-CHEMICAL
metalloproteinase-9	I-CHEMICAL
expression	O
and	O
dysregulated	O
Veillonella	B-BACTERIA
parvula	I-BACTERIA
colonization.	O

Halitosis	B-DISEASE
severity	O
correlated	O
with	O
elevated	O
hydrogen	B-PROCESS
sulfide	I-PROCESS
production	I-PROCESS
by	O
Prevotella	B-BACTERIA
intermedia	I-BACTERIA
bacterial	O
populations.	O

The	O
oil-pulling	B-PROCESS
intervention	I-PROCESS
reduced	O
Streptococcus	B-BACTERIA
mutans	I-BACTERIA
counts	O
while	O
improving	O
gingival	B-PROCESS
inflammation	I-PROCESS
markers.	O

Burning	B-DISEASE
mouth	I-DISEASE
syndrome	I-DISEASE
patients	O
exhibited	O
altered	O
taste	O
receptor	O
function	O
and	O
modified	O
Candida	B-BACTERIA
tropicalis	I-BACTERIA
oral	O
colonization.	O

Dental	O
implant	O
periimplantitis	B-DISEASE
involved	O
enhanced	O
Prevotella	B-BACTERIA
nigrescens	I-BACTERIA
biofilm	B-PROCESS
formation	I-PROCESS
and	O
increased	O
bone	B-PROCESS
resorption	I-PROCESS
markers.	O

The	O
probiotics	B-PROCESS
reduced	O
Porphyromonas	B-BACTERIA
gingivalis	I-BACTERIA
virulence	O
factors	O
while	O
enhancing	O
protective	O
immunoglobulin	B-CHEMICAL
A	I-CHEMICAL
secretion.	O

Oral	B-DISEASE
candidiasis	I-DISEASE
development	O
associated	O
with	O
decreased	O
Lactobacillus	B-BACTERIA
salivarius	I-BACTERIA
levels	O
and	O
impaired	O
antifungal	B-CHEMICAL
peptide	I-CHEMICAL
production.	O

Aggressive	O
periodontitis	B-DISEASE
patients	O
showed	O
elevated	O
elastase	B-CHEMICAL
enzyme	O
activity	O
and	O
increased	O
Campylobacter	B-BACTERIA
rectus	I-BACTERIA
colonization	O
density.	O

The	O
green	O
tea	O
extract	O
inhibited	O
Streptococcus	B-BACTERIA
mutans	I-BACTERIA
glucan	B-PROCESS
synthesis	I-PROCESS
while	O
reducing	O
dental	B-PROCESS
plaque	I-PROCESS
accumulation.	I-PROCESS

Oral	B-DISEASE
cancer	I-DISEASE
chemotherapy	B-PROCESS
altered	O
taste	O
perception	O
and	O
modified	O
Rothia	B-BACTERIA
mucilaginosa	I-BACTERIA
bacterial	O
population	O
dynamics.	O

Xerostomia	B-DISEASE
patients	O
demonstrated	O
reduced	O
antimicrobial	B-CHEMICAL
peptide	I-CHEMICAL
levels	O
and	O
increased	O
Candida	B-BACTERIA
glabrata	I-BACTERIA
opportunistic	O
colonization.	O

The	O
fluoride	B-CHEMICAL
treatment	O
enhanced	O
enamel	B-PROCESS
remineralization	I-PROCESS
while	O
selectively	O
reducing	O
cariogenic	O
Streptococcus	B-BACTERIA
mutans	I-BACTERIA
populations.	O

Recurrent	O
aphthous	B-DISEASE
stomatitis	I-DISEASE
correlated	I-DISEASE
with	O
elevated	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor-alpha	I-CHEMICAL
levels	O
and	O
altered	O
Streptococcus	B-BACTERIA
oralis	I-BACTERIA
abundance.	O

Tongue	B-PROCESS
coating	I-PROCESS
accumulation    I-PROCESS
involved	O
increased	O
volatile	B-PROCESS
organic	I-PROCESS
compound	I-PROCESS
production	I-PROCESS
by	O
Solobacterium	B-BACTERIA
moorei	I-BACTERIA
bacteria.	O

Metabolomic	B-PROCESS
profiling	I-PROCESS
revealed	O
elevated	O
branched-chain	B-CHEMICAL
amino	I-CHEMICAL
acids	I-CHEMICAL
in	O
insulin-resistant	B-DISEASE
patients	O
with	O
altered	O
gut	O
microbiota	B-BACTERIA
composition.	O

The	O
liquid	B-PROCESS
chromatography-mass	I-PROCESS
spectrometry	I-PROCESS
analysis	O
detected	O
increased	O
indoxyl	B-CHEMICAL
sulfate	I-CHEMICAL
levels	O
during	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
progression.	O

Serum	O
metabolite	B-CHEMICAL
analysis	O
identified	O
decreased	O
choline	B-CHEMICAL
concentrations	O
correlating	O
with	O
Alzheimers	B-DISEASE
disease	I-DISEASE
cognitive	O
decline.	O

Gas	B-PROCESS
chromatography	I-PROCESS
revealed	O
altered	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
profiles	O
in	O
multiple	B-DISEASE
sclerosis	I-DISEASE
patients	O
with	O
dysregulated	O
lipid	B-PROCESS
metabolism.	I-PROCESS

The	O
untargeted	B-PROCESS
metabolomics	I-PROCESS
approach	O
discovered	O
elevated	O
kynurenine	B-CHEMICAL
pathway	I-CHEMICAL
metabolites	B-CHEMICAL
in	O
depression	B-DISEASE
patients.	O

Nuclear	B-PROCESS
magnetic	I-PROCESS
resonance	I-PROCESS
spectroscopy	I-PROCESS
detected	O
increased	O
lactate	B-CHEMICAL
levels	O
during	O
septic	B-PROCESS
shock	I-PROCESS
inflammatory	B-PROCESS
responses.	I-PROCESS

Plasma	B-PROCESS
amino	I-PROCESS
acid	I-PROCESS
profiling	I-PROCESS
showed	O
decreased	O
arginine	B-CHEMICAL
availability	O
in	O
critically	O
ill	O
patients	O
with	O
immune	B-PROCESS
dysfunction.	I-PROCESS

The	O
targeted	O
analysis	O
revealed	O
elevated	O
homocysteine	B-CHEMICAL
concentrations	O
in	O
cardiovascular	B-DISEASE
disease	I-DISEASE
patients	O
with	O
methylation	B-PROCESS
defects.	I-PROCESS

Urine	B-PROCESS
metabolomics	I-PROCESS
identified	O
increased	O
3-hydroxykynurenine	B-CHEMICAL
levels	O
during	O
tryptophan	B-PROCESS
catabolism	I-PROCESS
in	O
cancer	B-DISEASE
patients.	O

Mass	B-PROCESS
spectrometry	I-PROCESS
detected	O
altered	O
bile	B-CHEMICAL
acid	I-CHEMICAL
signatures	O
in	O
patients	O
with	O
non-alcoholic	B-DISEASE
fatty	I-DISEASE
liver	I-DISEASE
disease.	I-DISEASE

The	O
lipidomics	B-PROCESS
analysis	I-PROCESS
revealed	O
decreased	O
omega-3	B-CHEMICAL
fatty	I-CHEMICAL
acid	I-CHEMICAL
levels	O
in	O
inflammatory	B-DISEASE
bowel	I-DISEASE
disease	I-DISEASE
patients.	O

Serum	O
analysis	O
showed	O
elevated	O
asymmetric	B-CHEMICAL
dimethylarginine	I-CHEMICAL
concentrations	O
in	O
hypertensive	O
patients	O
with	O
endothelial	B-PROCESS
dysfunction.	I-PROCESS

The	O
metabolite	B-CHEMICAL
profiling	O
detected	O
increased	O
methylmalonic	B-CHEMICAL
acid	I-CHEMICAL
levels	O
in	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
deficient	O
elderly	O
patients.	O

Plasma	O
analysis	O
revealed	O
altered	O
acylcarnitine	B-CHEMICAL
profiles	O
in	O
patients	O
with	O
mitochondrial	B-DISEASE
respiratory	I-DISEASE
chain	I-DISEASE
disorders.	I-DISEASE

The	O
comprehensive	O
screening	O
identified	O
elevated	O
homovanillic	B-CHEMICAL
acid	I-CHEMICAL
concentrations	O
in	O
Parkinsons	B-DISEASE
disease	I-DISEASE
patients.	O

Capillary	B-PROCESS
electrophoresis	I-PROCESS
detected	O
decreased	O
glutathione	B-CHEMICAL
levels	O
during	O
oxidative	B-PROCESS
stress	I-PROCESS
in	O
diabetes	B-DISEASE
patients.	O

The	O
targeted	O
approach	O
revealed	O
increased	O
quinolinic	B-CHEMICAL
acid	I-CHEMICAL
concentrations	O
in	O
patients	O
with	O
neurodegenerative	B-DISEASE
diseases.	I-DISEASE

Serum	O
profiling	O
showed	O
elevated	O
ceramide	B-CHEMICAL
levels	O
in	O
patients	O
with	O
insulin	B-PROCESS
resistance	I-PROCESS
and	O
metabolic	B-DISEASE
syndrome.	I-DISEASE

The	O
analysis	O
identified	O
decreased	O
S-adenosylmethionine	B-CHEMICAL
concentrations	O
in	O
patients	O
with	O
hepatic	B-PROCESS
methylation	I-PROCESS
dysfunction.	I-PROCESS

